Ask AI

GPRC5D-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Clinical Evidence and Practice Implications

Slideset

Released: September 03, 2026

See Activity Collection

These slides cover the evolving role of GPRC5D-directed bispecific antibodies in relapsed/refractory multiple myeloma. Take a look at evidence supporting CAR T-cell therapies and bispecific antibodies across the treatment continuum and explore considerations for treatment selection and sequencing of GPRC5D-directed therapy in the current treatment landscape, emerging data for talquetamab-based strategies, and factors that may influence outcomes following prior targeted therapy. The activity also addresses practical approaches to GPRC5D-directed bispecific antibody dosing, toxicity prevention, management, and patient counseling to support safe and effective integration of talquetamab into clinical practice.

GPRC5D BsAbs in RR MM

Activity Information

Released: September 03, 2026